Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the Annual
Report for 2013 now is available at the company’s website: www.medivir.com.
Annual Report 2013
“2013 was, without doubt, one of the most eventful years in Medivir’s 25-year
history! The biggest single event during the year was the marketing approval of
simeprevir – a pharmaceutical for the treatment of patients with chronic
hepatitis C that we have helped develop. The approval has allowed the launch of
simeprevir in Japan, Canada and the USA. Hepatitis C infected patients can now
be treated using a drug that we have helped discover and develop. It is a source
of great satisfaction to all Medivir employees, myself included, that we have
developed a pharmaceutical all the way from a concept to a new treatment that
can cure people and save lives,” said Medivir’s CEO, Maris Hartmanis, in his
CEO’s Statement in this year’s Annual Report.”
Medivir is an emerging research-based pharmaceutical company focused on
infectious diseases. Medivir has world class expertise in polymerase and
protease drug targets and drug development which has resulted in a strong
infectious disease R&D portfolio. The Company’s key pipeline asset is
simeprevir, a novel protease inhibitor for the treatment of hepatitis C that is
being developed in collaboration with Janssen R&D Ireland. The company is also
working with research and development in other areas, such as bone disorders and
neuropathic pain. Medivir has also a broad product portfolio with prescription
pharmaceuticals in the Nordics.
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.